Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

16.59 +0.05 (+0.33%)
Streaming Delayed Price Updated: 10:53 AM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday. AlloVir, Inc. (NASDAQ: ALVR) shares climbed 39% to $7.52... 
Via Benzinga
Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Dow Jumps 250 Points
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 250 points on Wednesday. 
Via Benzinga
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 40.0% to $1.4 during Wednesday's pre-market session. The company's market cap stands at $39.8 million.... 
Via Benzinga
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical... 
Via Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics's Earnings Outlook
Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying... 
Via Benzinga
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 71.1% to $0.36 during Tuesday's regular session. Brickell Biotech's stock is trading at a volume of... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and... 
Via Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
58 Biggest Movers From Yesterday
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
Via Benzinga
Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Calliditas Therapeutics (NASDAQ:CALT... 
Via Benzinga
31 Stocks Moving In Thursday's Mid-Day Session
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
Via Benzinga
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.